Stocks · News reference

AstraZeneca shares are trading lower following reports suggesting the company is in discussions with Bristol Myers Squibb to merge.

Aug 3, 2026, 11:43 AMBenzinga Newsdesk

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

AZN

Source: benzinga
Observed: Aug 3, 2026, 11:43 AM
Checked: Aug 3, 2026, 11:43 AM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

Zacks Investment ResearchAug 27, 2026, 4:11 PMNa
SMMT Rises on Akeso's Win in Phase III Biliary Tract Cancer Study
Summit Therapeutics' partner Akeso announced positive phase III HARMONi-GI1 study results showing ivonescimab plus chemotherapy achieved superior overall survival compared to AstraZeneca's Imfinzi plus chemotherapy in advanced biliary tract cancer patients. The drug also met key secondary endpoints for progression-free survival and objective response rate. These results strengthen ivonescimab's development case beyond its initial NSCLC focus into colorectal and genitourinary cancers.
Read original at zacks-investment-research
SMMT AZN MRK
BenzingaAug 27, 2026, 12:02 PMVandana Singh
AstraZeneca, Amgen Score Phase 3 Win in Debilitating Swallowing Disease
AstraZeneca & Amgen’s Tezspire achieves significant Phase 3 CROSSING trial results in eosinophilic esophagitis (EoE) treatment.
Read original at benzinga
AMGN AZN
BenzingaAug 27, 2026, 11:05 AMBenzinga Newsdesk
AstraZeneca, Amgen Report Phase III Results For TEZSPIRE In Eosinophilic Esophagitis; TEZSPIRE Meets Key Endpoints In Phase III CROSSING Trial
Statistically significant and clinically meaningful disease and symptom improvements compared to placebo maintained through week 52Efficacy in a third epithelial-driven inflammatory disease supports broad potential of
Read original at benzinga
AMGN AZN
BenzingaAug 27, 2026, 6:24 AMBenzinga Newsdesk
Amgen And AstraZeneca's TEZSPIRE Meets Both Co-Primary And All Key Secondary Endpoints In Phase 3 CROSSING Trial For Eosinophilic Esophagitis
Statistically Significant and Clinically Meaningful Disease and Symptom Improvements Compared to Placebo Maintained Through Week 52Efficacy in a Third Epithelial-Driven Inflammatory Disease Supports Broad Potential of
Read original at benzinga
AMGN AZN

AstraZeneca shares are trading lower following reports suggesting the company is in discussions with Bristol Myers Squibb to merge.

Connected markets

Related headlines

SMMT Rises on Akeso's Win in Phase III Biliary Tract Cancer Study

AstraZeneca, Amgen Score Phase 3 Win in Debilitating Swallowing Disease

AstraZeneca, Amgen Report Phase III Results For TEZSPIRE In Eosinophilic Esophagitis; TEZSPIRE Meets Key Endpoints In Phase III CROSSING Trial

Amgen And AstraZeneca's TEZSPIRE Meets Both Co-Primary And All Key Secondary Endpoints In Phase 3 CROSSING Trial For Eosinophilic Esophagitis